Q-omics provides the consensus-scored SH3RF2 profile across patient tissues and cancer cell-line models. SH3RF2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SH3RF2 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, SH3RF2 RNA expression shows 14,897 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, THCA, and TGCT as cancer lineages where SH3RF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3RF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3RF2 survival associations across molecular data types. SH3RF2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3RF2 RNA expression–survival associations across cancer types. High SH3RF2 expression shows unfavorable associations in UVM, PAAD and THCA, but favorable associations in READ, HNSC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SH3RF2 RNA expression.
This table summarizes SH3RF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SH3RF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3RF2 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRP, LUSC, LIHC and KIRC. The THCA box plot shows higher SH3RF2 RNA expression in normal versus tumor tissue (log2 FC = −0.960, t-test p < 0.001).
This table shows molecular features associated with SH3RF2 in patient tissues and cancer cell lines. In patient samples, SH3RF2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3RF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
